Find the Right Market Report

Search thousands of industry reports, market insights, and research studies in one place.

Not sure where to start? Try one of these:
Explore healthcare market intelligence and industry insights
Towards Healthcare

Hyaluronic Acid Companies, Growth and Strategic Expansion Initiatives 2026

Date : 20 March 2026

Top Companies in the Hyaluronic Acid Market and Company Latest Updates 2026

Hyaluronic Acid Market Companies are Allergan, Sanofi, Genzyme Corporation, Salix Pharmaceuticals, F. Hoffmann-La Roche AG, Galderma Laboratories L.P

All your Hyaluronic Acid Market information, organized and easy to use. Our experts have created a platform with market insights, data, country and company details, and competitor strategies; everything under one roof:   Visit the dashboard

Company Offerings

Company Headquarters Latest Update
Allergan Ireland In September 2025, Allergan Aesthetics, an AbbVie organization, launched the "Naturally You with Injectable Hyaluronic Acid Fillers" campaign, aimed to provide clear, factual education about HA injectable fillers. This initiative mainly focuses on correcting misinformation to raise understanding and celebrate the safe, natural-looking results possible with hyaluronic acid injectable fillers.
Sanofi France Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline.
Genzyme Corporation United States Genzyme’s single-injection management for knee osteoarthritis remains a foremost product in the worldwide viscosupplementation.
Salix Pharmaceuticals United States In July 2025, Bausch Health Companies Inc. and its gastroenterology (GI) business, Salix Pharmaceuticals, announced its novel direct-to-consumer (DTC) “I Wish I Knew” campaign for Xifaxan, the first and only medicine FDA-approved for the lower challenges of overt hepatic encephalopathy (OHE) recurrence in adults.
F. Hoffmann-La Roche AG Switzerland F. Hoffmann-La Roche Ltd. (Roche) continues to focus on its core pharmaceuticals and diagnostics divisions.
Galderma Laboratories L.P United States In November 2025, Galderma unveiled significant novel data from its range of pioneering Restylane hyaluronic acid (HA) injectables, highlighting its versatility in enhancing the chin profile with Restylane Lyft.

Supply Chain Analysis

R&D:

  • Increasing research and development (R&D) processes in endoscopic submucosal dissection are microbial strain improvement and fermentation, downstream processing, chemical modification and cross-linking, and characterization and quality control
  • Key Players: Bloomage Biotechnology Corporation Limited, and Allergan Aesthetics (AbbVie)

Manufacturing Processes:

  • Major manufacturing processes in hyaluronic acid include microbial fermentation, extraction from animal tissue, downstream processing/purification, cross-linking, and sterilization.
  • Key Players: Contipro a.s., and Kewpie Corporation

Patient Services:

  • Patient services involved in hyaluronic acid (HA) treatments span the dermatology, ophthalmology, orthopaedics, and wound care, focusing on lubrication, hydration, and tissue repair.
  • Key Players: Seikagaku Corporation and Anika Therapeutics

Market Growth

The global hyaluronic acid market size was estimated at USD 11.54 billion in 2025 and is predicted to increase from USD 12.4 billion in 2026 to approximately USD 23.65 billion by 2035, expanding at a CAGR of 7.44% from 2026 to 2035.

Hyaluronic Acid Market Size is USD 12.4 Billion in 2026.

Recent Developments in the Hyaluronic Acid Market

  • In February 2026, Galderma, the pure-play dermatology category leader, announced the launch of Restylane Defyne and Restylane Refyne, the first OBT‑driven hyaluronic acid injectables ever authorized in Japan.
  • In July 2025, Waldencast plc, a worldwide multi-brand beauty and wellness platform, announced that it had acquired Novaestiq Corp., a growth-oriented aesthetic and medical dermatological innovations organization, as well as the U.S. rights to the Saypha line of hyaluronic acid (HA) injectable gels.
  • In July 2025, Avanos Medical, Inc., announced the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC (CMM), a privately held company based in Raleigh, NC.
  • In February 2025, Crown Laboratories, Inc., a privately held, worldwide innovative leader in the skincare industry, announced the effective closing of its acquisition of Revance Therapeutics, Inc., a biotechnology organization aimed at setting the novel standard in healthcare with advanced aesthetic and therapeutic products.

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.

Talk to an Analyst Contact Sales